Eli Lilly Highlights the P-I/II Trial Data of Olomorasib for Treating Advanced Solid Tumors at ASCO 2024
Shots:
- The P-I/II (LOXO-RAS-20001) trial assesses the safety, tolerability & preliminary efficacy of olomorasib alone (P-Ia) & in combination with other therapies (P-Ib) to treat KRAS G12C-mutated advanced solid tumors. Recruitment in P-III (SUNRAY-01) trial of olomorasib + Keytruda or Keytruda + CT in 1L NSCLC is ongoing
- Olomorasib monotx., as of Mar 2024, depicted a 35% ORR (37/105) in non-CRC solid tumors with mPFS of 7.1mos. & 7.9mos. in KRAS G12C inhibitor-naive non-CRC solid tumors & NSCLC, respectively, and 41% (16/39) ORR with 8.1mos. mPFS in KRAS G12C inhibitor-experienced NSCLC. Preliminary CNS activity was seen in NSCLC patients with brain metastases
- Olomorasib + Keytruda showed a 77% (13/17) ORR with mPFS not attained in 1L metastatic KRAS G12C-mutated NSCLC. TRAEs leading to discontinuation were 3% for olomorasib, 11% for Keytruda & 5% for both
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Receives the US FDA’s Approval for Retevmo (Selpercatinib) to Treat Thyroid Cancer or Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
